TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 151 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $22,151,773 | +26.2% | 984,961 | +18.0% | 0.15% | +84.1% |
| Q4 2022 | $17,559,229 | -14.6% | 834,961 | 0.0% | 0.08% | -32.2% |
| Q3 2022 | $20,573,000 | +1.7% | 834,961 | 0.0% | 0.12% | -61.2% |
| Q2 2022 | $20,231,000 | -9.6% | 834,961 | -3.9% | 0.31% | +13.9% |
| Q1 2022 | $22,388,000 | -20.6% | 868,778 | -4.4% | 0.27% | -3.9% |
| Q4 2021 | $28,214,000 | +53.3% | 908,951 | +19.8% | 0.28% | +265.4% |
| Q3 2021 | $18,404,000 | +122.4% | 758,951 | +33.8% | 0.08% | +69.6% |
| Q2 2021 | $8,276,000 | +26.0% | 567,183 | +115.6% | 0.05% | +27.8% |
| Q1 2021 | $6,568,000 | – | 263,013 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |